741 related articles for article (PubMed ID: 14630925)
1. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
2. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
3. Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion.
Roy M; Reiland J; Murry BP; Chouljenko V; Kousoulas KG; Marchetti D
Neoplasia; 2005 Mar; 7(3):253-62. PubMed ID: 15799825
[TBL] [Abstract][Full Text] [Related]
4. Heparanase and a synthetic peptide of heparan sulfate-interacting protein recognize common sites on cell surface and extracellular matrix heparan sulfate.
Marchetti D; Liu S; Spohn WC; Carson DD
J Biol Chem; 1997 Jun; 272(25):15891-7. PubMed ID: 9188488
[TBL] [Abstract][Full Text] [Related]
5. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis.
Roy M; Marchetti D
J Cell Biochem; 2009 Feb; 106(2):200-9. PubMed ID: 19115257
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative CREB inhibits heparanase functionality and melanoma cell invasion.
Aucoin R; Reiland J; Roy M; Marchetti D
J Cell Biochem; 2004 Oct; 93(2):215-23. PubMed ID: 15368349
[TBL] [Abstract][Full Text] [Related]
7. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases.
Roskams T; Rosenbaum J; De Vos R; David G; Desmet V
Hepatology; 1996 Sep; 24(3):524-32. PubMed ID: 8781318
[TBL] [Abstract][Full Text] [Related]
8. Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin.
Han J; Hiebert LM
Vascul Pharmacol; 2013; 59(3-4):112-8. PubMed ID: 23939434
[TBL] [Abstract][Full Text] [Related]
9. Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Hoß SG; Grundmann M; Benkel T; Gockel L; Schwarz S; Kostenis E; Schlesinger M; Ilan N; Vlodavsky I; Bendas G
Thromb Haemost; 2018 Oct; 118(10):1803-1814. PubMed ID: 30235481
[TBL] [Abstract][Full Text] [Related]
10. Heparan sulfate chains with antimitogenic properties arise from mesangial cell-surface proteoglycans.
Wang A; Miralem T; Templeton DM
Metabolism; 1999 Oct; 48(10):1220-9. PubMed ID: 10535382
[TBL] [Abstract][Full Text] [Related]
11. Heparan sulfate regulates targeting of syndecan-1 to a functional domain on the cell surface.
Yang Y; Børset M; Langford JK; Sanderson RD
J Biol Chem; 2003 Apr; 278(15):12888-93. PubMed ID: 12566461
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo.
de Boer C; Armstrong Z; Lit VAJ; Barash U; Ruijgrok G; Boyango I; Weitzenberg MM; Schröder SP; Sarris AJC; Meeuwenoord NJ; Bule P; Kayal Y; Ilan N; Codée JDC; Vlodavsky I; Overkleeft HS; Davies GJ; Wu L
Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2203167119. PubMed ID: 35881786
[TBL] [Abstract][Full Text] [Related]
13. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2.
Clayton A; Thomas J; Thomas GJ; Davies M; Steadman R
Kidney Int; 2001 Jun; 59(6):2084-94. PubMed ID: 11380810
[TBL] [Abstract][Full Text] [Related]
14. Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains.
Kato M; Wang H; Bernfield M; Gallagher JT; Turnbull JE
J Biol Chem; 1994 Jul; 269(29):18881-90. PubMed ID: 8034644
[TBL] [Abstract][Full Text] [Related]
15. Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis.
Patel VN; Knox SM; Likar KM; Lathrop CA; Hossain R; Eftekhari S; Whitelock JM; Elkin M; Vlodavsky I; Hoffman MP
Development; 2007 Dec; 134(23):4177-86. PubMed ID: 17959718
[TBL] [Abstract][Full Text] [Related]
16. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
17. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation.
Fisher MC; Li Y; Seghatoleslami MR; Dealy CN; Kosher RA
Matrix Biol; 2006 Jan; 25(1):27-39. PubMed ID: 16226436
[TBL] [Abstract][Full Text] [Related]
18. Perlecan is responsible for thrombospondin 1 binding on the cell surface of cultured porcine endothelial cells.
Vischer P; Feitsma K; Schön P; Völker W
Eur J Cell Biol; 1997 Aug; 73(4):332-43. PubMed ID: 9270876
[TBL] [Abstract][Full Text] [Related]
19. Heparan sulfate proteoglycan expression in human lung-cancer cells.
Nackaerts K; Verbeken E; Deneffe G; Vanderschueren B; Demedts M; David G
Int J Cancer; 1997 Jun; 74(3):335-45. PubMed ID: 9221815
[TBL] [Abstract][Full Text] [Related]
20. Heparanase mechanisms of melanoma metastasis to the brain: Development and use of a brain slice model.
Murry BP; Blust BE; Singh A; Foster TP; Marchetti D
J Cell Biochem; 2006 Feb; 97(2):217-25. PubMed ID: 16288472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
